CIK 0001022079 · Large accelerated filer
QUEST DIAGNOSTICS INC
Sign in to watch- Ticker
- DGX
- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 161387862
- Phone
- 9735202700
- Business address
- 500 PLAZA DRIVE, SECAUCUS, NJ, 07094
- Former names
- CORNING CLINICAL LABORATORIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,715,054
- in 4 filings, $13.7M under 10b5-1 plans
Net −$13,715,054. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-03 | Ramachandran Subu SVP, Regional Businesses | Grant or award | +352 | 2,832 | ||
| 2026-11-03 | Ramachandran Subu SVP, Regional Businesses | Grant or award · Non-Qualifed Stock Option (right to buy) | +1,386 | 1,386 | ||
| 2026-11-03 | Doherty Catherine T. Executive Vice President | Grant or award 10b5-1 | +4,827 | 71,949 | ||
| 2026-11-03 | Doherty Catherine T. Executive Vice President | Option exercise 10b5-1 | +22,105 | $121.81 | $2.7M | 94,054 |
| 2026-11-03 | Doherty Catherine T. Executive Vice President | Sale 10b5-1 | −3,818 | $245.45 | $937K | 90,236 |
| 2026-11-03 | Doherty Catherine T. Executive Vice President | Sale 10b5-1 | −5,990 | $246.26 | $1.5M | 84,246 |
| 2026-11-03 | Doherty Catherine T. Executive Vice President | Sale 10b5-1 | −1,151 | $246.98 | $284K | 83,095 |
| 2026-11-03 | Doherty Catherine T. Executive Vice President | Sale 10b5-1 | −2,358 | $248.38 | $586K | 80,737 |
| 2026-11-03 | Doherty Catherine T. Executive Vice President | Sale 10b5-1 | −3,004 | $249.40 | $749K | 77,733 |
| 2026-11-03 | Doherty Catherine T. Executive Vice President | Sale 10b5-1 | −2,877 | $250.49 | $721K | 74,856 |
| 2026-11-03 | Doherty Catherine T. Executive Vice President | Sale 10b5-1 | −2,907 | $251.24 | $730K | 71,949 |
| 2026-11-03 | Doherty Catherine T. Executive Vice President | Option exercise · Non-Qualifed Stock Option (right to buy) 10b5-1 | −22,105 | $121.81 | $2.7M | 0 |
| 2026-11-03 | DELANEY MARK E SVP & Chief Commercial Officer | Grant or award | +2,615 | 12,975 | ||
| 2026-10-26 | PFEIFFER GARY M Director | Sale 10b5-1 | −1,203 | $243.00 | $292K | 29,802 |
| 2026-10-21 | CARTER ROBERT B Director | Other acquisition | +10 | $235.93 | $2K | 3,874 |
| 2026-10-21 | SAMAD SAM Executive Vice President & CFO | Grant or award | +90 | $235.94 | $21K | 33,568 |
| 2026-10-21 | Gregg Vicky B Director | Grant or award | +63 | $235.94 | $15K | 18,449 |
| 2026-10-21 | KUPPUSAMY KARTHIK SVP, Clinical Solutions | Other acquisition | +33 | $235.94 | $8K | 13,619 |
| 2026-10-21 | Lassiter Wright III Director | Other acquisition | +6 | $235.96 | $1K | 10,329 |
| 2026-10-21 | Plewman Patrick SVP for Diagnostic Services | Other acquisition | +41 | $235.94 | $10K | 15,334 |
Page 1 of 21 · 402 trades